COVID19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group 1: will receive sitagliptin 100 mg daily for 5days in addition to standard treatment of COVID19. Intervention 2: Intervention group 2: will receive spironolactone 1
Sponsors
Boushehr University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: admitted patients in Bushehr's Shohadaye_Khalije_Fars hospital due to COVID19 diagnosis confirmed by Rt-PCR age equal or more than 20 Male and female OPD patients with confirmed or probable SARS-CoV-2 infection according to WHO and CDC definitions referred to Motahari Clinic.
Exclusion criteria
Exclusion criteria: pregnancy positive history of spironolactone or DPP4 inhibitor consumption contraindications for drug intervention consumption (Plasma Acid/base, Electrolyte or Glucose abnormalities) hypersensitivity to drugs patient dissatisfaction intubation and mechanical ventilation at admission onset
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The blood oxygen saturation percentage is examined as an index of oxygenation status. Timepoint: first, third and fifth day of study. Method of measurement: pulsoxymeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lung involvement description and percentage in lung HRCT scan. Timepoint: first and fifth day of study. Method of measurement: Lung HRCT scan which will be reported by a radiologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarhad Abbasi
Boushehr University of Medical Sciences
Outcome results
None listed